Indoco Remedies Ltd.

NSE: INDOCO BSE: 532612 SECTOR: Pharmaceuticals & Drugs

473.05
-8.35 (-1.73%)
NSE: 20 Sep 04:13 PM

Price Summary

Today's High

₹ 485

Today's Low

₹ 469.5

52 Week High

₹ 530.25

52 Week Low

₹ 242.1

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.

Company Essentials

Market Cap

4359.17 Cr.

Enterprise Value

4603.33 Cr.

No. of Shares

9.22 Cr.

P/E

37.98

P/B

5.39

Face Value

₹ 2

Div. Yield

0.32%

Book Value (TTM)

₹  87.74

CASH

14.05 Cr.

DEBT

258.21 Cr.

Promoter Holding

58.54%

EPS (TTM)

₹  12.45

Sales Growth

12.14%

ROE

12.75 %

ROCE

15.6 %

Profit Growth

281.03 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

SPADE SURGE-RADIUS WARREN WARREN-EXCEL SPERA

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Ratios

Sales Growth

1 Year12.14%
3 Year6.11%
5 Year4.3%

Profit Growth

1 Year281.03%
3 Year30.9%
5 Year2.34%

ROE%

1 Year12.75%
3 Year5.31%
5 Year6.95%

ROCE %

1 Year15.6%
3 Year7.54%
5 Year8.41%

Debt/Equity

0.3358

Price to Cash Flow

53.05

Interest Cover Ratio

6.91231702706109

CFO/PAT (5 Yr. Avg.)

2.35546950620906

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2021 58.54 0
Mar 2021 58.69 0
Dec 2020 58.69 0
Sep 2020 58.69 0
Jun 2020 58.69 0
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 30.8963371224891% for the Past 3 years.
  • Company’s PEG ratio is 0.135156737705381.
  • The company has an efficient Cash Conversion Cycle of 76.4838769614003 days.
  • The company has a good cash flow management; CFO/PAT stands at 2.35546950620906.
  • The company has a high promoter holding of 58.54%.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 17.5165541894138.

 Limitations

  • The company has shown a poor revenue growth of 6.10772793926533% for the Past 3 years.
  • Company has a poor ROE of 5.31413150644757% over the past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021
Net Sales 275.86 327.65 331.94 304.85 386.49
Total Expenditure 227 267.47 271.98 250.28 299.68
Operating Profit 48.86 60.18 59.96 54.57 86.81
Other Income 0.26 0.52 0.37 1.97 0.86
Interest 5.75 5.89 6.03 4.55 4.23
Depreciation 19.13 18.57 16.88 18.54 22.23
Exceptional Items 0 0 0 0 0
Profit Before Tax 24.24 36.24 37.42 33.45 61.21
Tax 7.01 11.13 12.28 8.54 21.6
Profit After Tax 17.23 25.11 25.14 24.91 39.61
Adjusted EPS (Rs) 1.87 2.72 2.73 2.7 4.3

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Net Sales 1072.06 1038.21 967.73 1105.99 1240.3
Total Expenditure 917.4 906.73 891.03 985.01 1022.67
Operating Profit 154.66 131.49 76.7 120.98 217.63
Other Income 6.1 8.15 6.71 4.79 9.05
Interest 6.16 23.51 21.09 26.25 22.22
Depreciation 63.27 67.71 71.56 70.81 73.12
Exceptional Items 0 0 0 0 0
Profit Before Tax 91.34 48.43 -9.24 28.71 131.35
Tax 13.88 7.23 -6.4 4.46 38.96
Net Profit 77.46 41.2 -2.84 24.25 92.39
Adjusted EPS (Rs.) 8.41 4.47 -0.31 2.63 10.03

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Equity and Liabilities
Share Capital 18.43 18.43 18.43 18.43 18.43
Total Reserves 633.45 657.13 642.65 661.73 750.5
Borrowings 132.31 123.28 128.66 96.93 96.94
Other N/C liabilities 14.66 2 -12.31 3.98 61.36
Current liabilities 390.37 416.89 445.33 459.17 408.54
Total Liabilities 1189.22 1217.72 1222.76 1240.24 1335.76
Assets
Net Block 439.75 488.73 467.52 589.62 569.91
Capital WIP 40.33 75.78 141.23 7.32 25.12
Intangible WIP 50.3 59.78 44.2 43.38 42.98
Investments 2.82 2.61 2.44 2.45 2.45
Loans & Advances 66.34 33.58 21.75 26.07 63.95
Other N/C Assets 19.51 20.09 9.11 9.64 9.39
Current Assets 570.18 537.15 536.5 561.76 621.95
Total Assets 1189.22 1217.72 1222.76 1240.24 1335.76
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Profit from operations 91.34 48.43 -9.24 28.71 131.35
Adjustment 64.31 97.82 89.34 99.51 109.71
Changes in Assets & Liabilities -44.07 -13.59 55.66 -1.65 -139.14
Tax Paid -23.77 -9.89 -3.62 -3.92 -19.75
Operating Cash Flow 87.81 122.76 132.13 122.66 82.17
Investing Cash Flow -170.54 -135.43 -103.76 -55.95 -66.7
Financing Cash Flow 132.4 -38.77 -16.14 -63.95 -29.83
Net Cash Flow 49.67 -51.44 12.23 2.76 -14.35

Corporate Actions

Investors Details

PARTICULARS Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021
Promoters 58.69 58.69 58.69 58.69 58.54
kare aruna suresh 5.2 5.2 5.2 5.2 5.19
kare suresh govind 4.41 4.41 4.41 4.41 4.4
milind s panandikar 0.01 0.01 0.01 0.01 0.01
panandikar aditi milind 0 6.03 6.03 6.03 6.02
pratima ajit vaidya 0.03 0.03 0.03 0.03 0.03
ramani madhura anup 5.63 5.63 5.63 5.63 5.61
sharda ramnath kare 0.04 0.04 0.04 0.04 0.04
mahika milind panandikar 0.01 0.01 0.01 0.01 0.01
milind s panandikar 0.01 0.01 0.01 0.01 0.01
pratima ajit vaidya 0.03 0.03 0.03 0.03 0.03
rohan anup ramani 0.01 0.01 0.01 0.01 0.01
shanteri investment pvt l... 17.12 17.12 17.12 17.12 17.07
sharda ramnath kare 0.04 0.04 0.04 0.04 0.04
mahika milind panandikar 0.01 0.01 0.01 0.01 0.01
rohan anup ramani 0.01 0.01 0.01 0.01 0.01
shanteri investment pvt l... 17.12 17.12 17.12 17.12 17.07
spa holdings pvt ltd 19.9 19.9 19.9 19.9 19.85
sudha m pai 0.01 0.01 0.01 0.01 0.01
kare suresh govind huf 0.3 0 0.3 0.3 0.3
panandikar aditi milind 0 6.03 6.03 6.03 6.02
kare suresh govind - huf 0 0 0 0 0
megh milind panandikar 0.01 0.01 0.01 0.01 0.01
rohan ramani 0 0 0 0 0
panandikar aditi 6.03 0 0 0 0
kare suresh govind -huf 0 0.3 0 0 0
PARTICULARS Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021
Public 24.77 24.42 21.32 19.39 19.94
ashish agarwal 1.59 1.09 0 0 0
ashish agarwal 1.59 1.09 0 0 0
iepf 0.06 0.06 0.06 0.06 0.06
mangeshi investment priva... 0 1.27 1.27 1.27 1.26
mangeshi investment pvt. ... 0 0 0 0 0
mangeshi investments priv... 1.27 0 0 0 0
llp 0 0 0 0 0.06
mangeshi investment priva... 0 1.27 1.27 1.27 1.26
PARTICULARS Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021
FII/DII 16.54 16.89 19.99 21.92 21.52
idfc core equity fund 0 0 0 0 0
icici prudential pharma h... 0 2.2 0 0 0
icici prudential pharma h... 1.91 0 0 0 0
dsp top 100 equity fund 2.29 0 0 0 0
hdfc trustee co ltd a/c h... 0 0 0 0 0
icici prudential pharma h... 0 0 0 0 0
reliance capital trustee ... 0 0 0 0 0
reliance capital trustee ... 7.49 0 0 0 0
reliance capital trustee ... 0 7.53 0 0 0
sundaram mutual fund a/c ... 0 1.38 0 0 1.3
icici prudent pharma heal... 0 0 3.7 4.11 0
nippon life india trustee... 0 0 6.66 6.64 0
sundaram mutual fund a/c ... 0 0 1.69 1.6 0
aditya birla sun life tru... 0 0 0 1.09 0
dsp healthcare fund 0 0 0 1.01 0
adity birla life trustee ... 0 0 0 0 1.23
dsp healthcare ltd 0 0 0 0 1.01
icici prudential pharma h... 0 0 0 0 4.82
nippon life india trustee... 0 0 0 0 6.2
sundaram mutual fund a/c ... 0 1.38 0 0 1.3

Ratings & Research Reports

Company Presentations

Company News

Indoco Remedies informs about press release 27 Aug 2021, 4:59PM Indoco Remedies’ Clinical Research Organisation gets accreditation from UKMHRA27 Aug 2021, 1:12PM Indoco Remedies informs about analyst meet20 Aug 2021, 9:51AM ICRA upgrades Indoco Remedies’ long term rating to ‘AA-’ 23 Jul 2021, 5:11PM Indoco Remedies informs about board meeting13 Jul 2021, 10:40AM Indoco Remedies informs about book closure2 Jul 2021, 3:46PM Indoco Remedies informs about annual secretarial compliance report15 Jun 2021, 10:38AM Indoco Remedies informs about transcript of conference call 4 Jun 2021, 2:51PM Indoco Remedies informs about outcome of board meeting25 May 2021, 4:20PM Indoco Remedies informs about conference call19 May 2021, 10:43AM Indoco Remedies informs about publication of board meeting notice5 May 2021, 1:45PM Indoco Remedies launches Brinzolamide Ophthalmic Suspension 1% in United States9 Mar 2021, 12:28PM Indoco Remedies informs about board meeting13 Jan 2021, 10:28AM Indoco Remedies wins major tenders worth Rs 140 crore in Germany8 Dec 2020, 11:38AM Indoco Remedies informs about newspaper publication20 Oct 2020, 3:26PM Indoco Remedies launches Favipiravir 400 mg tablets in India 28 Sep 2020, 9:00AM Indoco Remedies informs about press release26 Sep 2020, 2:35PM Indoco Remedies gets USFDA’s nod for Apixaban Tablets14 Sep 2020, 10:34AM Indoco Remedies informs about press release14 Sep 2020, 10:29AM Indoco Remedies informs about press release6 Aug 2020, 10:44AM Indoco Remedies gets USFDA’s nod for Olanzapine Tablets6 Aug 2020, 10:01AM Indoco Remedies informs about con call4 Jun 2020, 10:42AM Indoco Remedies informs about board meeting1 Jun 2020, 10:27AM Indoco Remedies gets USFDA’s nod for Succinylcholine Chloride Injection USP26 May 2020, 1:16PM Indoco Remedies sends 11.7 lakh Paracetamol pills to Britain to battle COVID-1915 Apr 2020, 11:44AM

Indoco Remedies Stock Price Analysis and Quick Research Report. Is Indoco Remedies an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Indoco Remedies and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 82.174 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Indoco Remedies has a Debt to Equity ratio of 0.3358 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Indoco Remedies , the EPS growth was 281.021509462643 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Indoco Remedies has OPM of 17.546721853186 % which is a good sign for profitability.
     
  • ROE: Indoco Remedies have a average ROE of 12.7517278258582 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Brief about Indoco Remedies

X